BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11274765)

  • 21. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
    Lee KH; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Hwang HJ; Jung AR; Kim SH; Yun SC; Shin HJ
    Blood; 2011 Sep; 118(9):2609-17. PubMed ID: 21715313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
    Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation.
    Atta EH; de Oliveira DC; Bouzas LF; Nucci M; Abdelhay E
    PLoS One; 2014; 9(9):e107155. PubMed ID: 25188326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
    Kröger N; Sayer HG; Schwerdtfeger R; Kiehl M; Nagler A; Renges H; Zabelina T; Fehse B; Ayuk F; Wittkowsky G; Schmitz N; Zander AR
    Blood; 2002 Dec; 100(12):3919-24. PubMed ID: 12393448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
    Kato K; Yoshida N; Matsumoto K; Matsuyama T
    Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
    Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML.
    Schleuning M; Günther W; Tischer J; Ledderose G; Kolb HJ
    Bone Marrow Transplant; 2003 Aug; 32(3):243-50. PubMed ID: 12858194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
    Nakane T; Nakamae H; Koh H; Nakamae M; Hayashi Y; Nishimoto M; Yoshimura T; Inoue E; Inoue A; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Hino M
    Int J Hematol; 2011 Apr; 93(4):509-516. PubMed ID: 21394567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
    Grigull L; Beilken A; Schrappe M; Das A; Luecke T; Sander A; Stanulla M; Rehe K; Sauer M; Schmid H; Welte K; Lukacs Z; Gal A; Sykora KW
    Bone Marrow Transplant; 2005 Feb; 35(3):265-9. PubMed ID: 15580280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.